CytoDyn will host a webcast on June 21st to discuss open-ended data from the COVID-19 long-range trial and other developments

VANCOUVER, Wash., June 16, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Leronlimab, a CCR5 antagonist with potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer , Scott Kelly, MD, Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, MD, Chief Operating Officer and Head of Clinical Development, will webcast the investment community on Monday, June 21, 2021.

Management will fully discuss the results of the recently unblinded data from its long-range COVID-19 study, along with updates on COVID-19 studies in other countries, active studies on NASH and cancer, and regulatory advances.

Management will give approximately 60 minutes to answer questions that are asked online by analysts and investors.


Monday, June 21, 2021


1:00 p.m. PT / 4:00 p.m. ET

Dial in:



This is a “listen only” webcast that can be accessed on the CytoDyn company website at in the Investors / IR Calendar section and is archived for 30 days. Attendees are advised to register on the website, download and install the required software 15 minutes before the webcast begins. Please note that the following website is not operational until approx. 60 minutes before the start of the webcast, which can be reached via the following link:

The replay will be available approx. 60 minutes after the end of the webcast and can be accessed via the link above until July 21, 2021.


Cristina De Leon placeholder image
Office: 360.980.8524
[email protected]

Comments are closed.